Tarsus Pharmaceuticals, Inc. TARS Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s unrealized losses on investments (before tax)?
- Tarsus Pharmaceuticals, Inc. (TARS) reported unrealized losses on investments (before tax) of $389K in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s unrealized losses on investments (before tax) changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s unrealized losses on investments (before tax) increased by 1289.3% year-over-year, from $28K to $389K.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s unrealized losses on investments (before tax)?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s unrealized losses on investments (before tax) has grown at a -53.9% compound annual growth rate (CAGR), from $92K to $9K.
- What does unrealized losses on investments (before tax) mean?
- The total decrease in value of investment securities held by the company that have not yet been sold, calculated prior to any tax adjustments. Monitoring these losses provides insight into the volatility and risk profile of the company's investment strategy.